Is liver transplantation a reasonable alternative in neurologic Wilson disease patients resistant to chelators? Lessons from the French experience in 18 cases

Aurélia Poujois*, MD, PhD and France Woimant, MD on behalf of the French WD neuroLT group

National Reference Centre for Wilson’s disease, Neurology Department University Hospital Lariboisière, AP-HP, Paris, France
Is liver transplantation a reasonable alternative in neurologic Wilson disease patients resistant to chelators? Lessons from the french experience in 18 cases

French National reference center for Wilson Disease and other rare copper diseases
Neurology Department -Hôpital Universitaire Lariboisière, Paris, France

Aurélia POUJOIS, MD, PhD

Disclosure of Interest: Nothing to Disclose
Wilson Disease:
- an inherited disorder leading to toxic copper overload mainly in the liver and the brain.
- for 30% of patients, WD diagnosis can be made from the neurological symptoms. Can vary from 18–68% (depending of studies)*

In the French registry (619 patients):
- 33.5% of patients present neurological symptoms at diagnosis
- main initial symptoms: tremor (52.6%), dysarthria (52%), writing difficulties (31%), dystonia (27%), gait disorder (27%), drooling (23%) and dysphagia (14%).

Copper chelators or zinc therapy are effective treatments in most patients: neurological symptoms decrease or completely regress, although some may persist

However, neurological deterioration may happen

* EASL, 2012; Dalvi, 2014
Neurological worsening despite treatment

Day 1

WD Diagnosis
=> slow introduction of DP

2 months

Continuous worsening of symptoms
=> DP changed to Trientine

5 months

Continuous worsening of parkinsonism, dystonia, severe dysarthria and dysphagia
February 2002

MB, age 13
January 2000; WD Diagnosed
Mild dystonic features in LL
Abnormal MRI, KF rings

Treated by Trientine (acute side effect with DP)
=> Clinical neurological recovery in 1 year; MRI improved

June 2002: Holidays ... where treatment was interrupted ....
Neurological worsening after treatment discontinuation

February 2002

September 2002: 2 months after interruption of treatment

MB

2.5 years after diagnosis

« Fulminant » neurologic deterioration, two months after stopping treatment (generalized dystonia with “status dystonica”)

⇒ re-introduction of Trientine
⇒ Adjunction of zinc acetate
⇒ NO EFFECT,
INTRODUCTION

• Paradoxical worsening of neurological symptoms:
  o **11 - 24%** of neurological patients
  o With all three drugs: DP: 13.8 % >Trientine: 8 % > ZS: 4.3 % (Merle, 2007)
  o Irreversible in 44% of patients, resulting in severe disability or death despite optimal therapy (Prashanth, 2005; Svetel, 2009)

• Mechanisms of deterioration are unknown: many hypothesis
  1. Treatment too slow to act in very acute forms?
  2. Inefficacy of intracerebral chelation?
  3. Irreversible tissue damages already present?
  4. Direct effect of the treatment with rapid mobilization and redistribution of copper, resulting in high levels of copper in blood and brain leading to oxidative stress and accentuation of brain tissue damages?

⇒ slow increase of chelators doses recommended: « start low—go slow » regimen
How to deal with this dramatic situation?

⇒ As no other medical treatment exists, what could be the place of liver transplantation?
LIVER TRANSPLANTATION and WD

**Hepatic forms**
- The recommended therapeutic option in WD with:
  - Fulminant hepatic failure
  - Severe hepatic insufficiency
- Validated indications
- Good results with 87% survival rate at 15 years in a cohort of 121 French patients (Guillaud, 2014)

**Neurologic forms**
- Remains controversial in WD with worsening of neurological features despite treatment
- 15 cases-reports on LT for strict neurological indication published:
  - 32 patients, heterogeneous evaluation and follow-up
  - Various outcome

In France, thanks to rare diseases funding plans since 2005,
- **National reference network** for the care of Wilsonian patients
- National WD registry

---

**A NETWORK**

2 Reference Centres
- Coordinator site: Lariboisière Hospital (Paris)
- Constituent site: HFME Hospital (Lyon)

8 Competence Centres:
- Paris (Paul Brousse, Necker), Lille, Besançon, Marseille, Toulouse, Bordeaux, Rennes

1 Patient organization

**A MULTIDISCIPLINARY TEAM**

Paediatrics/Hepatology/Neurology
Molecular Biology Laboratory
Toxicology laboratory, metals and trace elements

**A NATIONAL WD REGISTRY**

www.cnrwilson.com
In France, thanks to rare disease funding plans since 2005,
• National reference network for the care of Wilsonian patients
• National WD registry

**Collaborative study** to report the French experience on
• LT in patients with pure neurological aggravation despite accurate medical treatment,
• With a special attention to:
  • the survival rate
  • the long term disability
  • the possible prognostic factors
LT IN NEUROLOGICAL WD PATIENTS: METHODS

- Retrospective study (June 1994 - June 2016)
- WD patients from the WD national registry, who underwent a LT for neurologic indication and fulfilled three conditions:
  1) Leipzig score for the diagnosis of WD > 4
  2) Constant neurological worsening despite a minimum of two months of appropriate copper chelation. Worsening defined as a minimum of:
     - 20% increase of the Unified WD Rating Scale (UWDRS) score
     - and a 2-point increase in the modified Rankin score (mRs).
  3) Severe neurological impairment with a mRs ≥ 4 at the time of LT

4: unable to walk without assistance and unable to attend to own bodily needs without assistance

5: severe disability; bedridden, incontinent and requiring constant nursing care and attention
LT IN NEUROLOGICAL WD PATIENTS: METHODS

• Retrospective study (June 1994 - June 2016)
• WD patients from the WD national registry, who underwent a LT for neurologic indication and fulfilled three conditions:
  1) Leipzig score for the diagnosis of WD > 4
  2) Constant neurological worsening despite a minimum of two months of appropriate copper chelation.
  3) Severe neurological impairment with a mRs ≥ 4 at the time of LT

• Neurologic worsening could be
  = primary in newly diagnosed and treated neurologic patients,
  = secondary to the interruption of chelators/ZS

• Criteria of non-inclusion:
  • hepatic indication of LT
  • severe neurological patients with stable condition or without recent worsening
CO-PRIMARY OUTCOMES

1) the overall survival rate
2) the disability at the last follow-up after LT as assessed by the mRS and the UWDRS.

Was arbitrarily considered as:

- **major improvement**: a decrease of UWDRS score above 66%,
- **moderate improvement**: a decrease of UWDRS score between 33% and 65%
- **mild improvement** or stable condition: a decrease below 33%

SECONDARY OUTCOMES

Evolution at the last follow-up of:

- ophthalmological score (KFR)
- brain MRI score
18 patients underwent LT for strict neurological indication in the 22 years period of time
  - Five liver transplant centres (8 in Paris, 4 in Bordeaux, 2 in Lyon, 2 in Besançon and 2 in Tours)
  - 60% had LT in the last six years

Concerned 14% of the patients of the registry with neurological phenotype

Characteristics of the 18 patients:
  - 10 males/8 females
  - Median age 18.5 years (range 16-20.8)
  - Median time between neurological worsening and LT: 6.7 months (5.3-14.5)
  - 13/18 (72%) had a primary worsening
  - Two pathological ATP7B mutations in all
LT IN NEUROLOGICAL WD PATIENTS: RESULTS

PATIENT CHARACTERISTICS AT INCLUSION BEFORE LT

- **Mild hepatic disease**
  - CHILD A for all patients, median MELD score 8.5 (7-10.8)
  - cirrhosis in native liver (18/18)

- **Severe neurological symptoms**
  - mRs = 5 in 89% patients: heavy disability
  - median UWDRS = 105 (79-117): severe neurological impairment
  - predominance of dystonia in 16/18 and Parkinsonism in 12/18
  - jejunostomy or gastrotomy in 78%; tracheostomy in 56%
  - brain MRI was abnormal in all patients; constant lenticular nucleus involvement

- **A fragile general condition**
  - 7/18 patients (40%): severe sepsis within 3 months before LT
  - 5/18 required an ICU admission for acute respiratory distress syndrome (ARDS) in the month prior LT.
• Cumulated survival rate was
  • **88.8% at 1 year**
  • 82.5% at 1.5 year
  • **72.2% at 3 years and 5 years**
LT IN NEUROLOGICAL WD PATIENTS: RESULTS

COPRIMARY OUTCOMES: (1) SURVIVAL RATE

- four patients (22%) deceased
- within a median interval of **13.8 (9-21) months** after LT
- due to sepsis of pulmonary origin

- were significantly associated with death:
  - **Severe sepsis (p=0.011)** in the month before LT
  - **ICU admission (p=0.001)** in the month before LT

- Tracheostomy and male gender tended to be associated with death
LT IN NEUROLOGICAL WD PATIENTS: RESULTS

• After a mean follow-up of 71+/−74 months (5.8 y)
• fourteen patients (78%) were alive.
LT IN NEUROLOGICAL WD PATIENTS: RESULTS

- After a mean follow-up of 71+/−74 months (5.8 y)
- Fourteen patients (78%) were alive.

COPRIMARY OUTCOMES: (2) DISABILITY AT THE LAST FOLLOW-UP: mRANKIN

- Median mRs improved from the pre-LT state: 1.5 (1-4) vs 5 (5-5); p<0.0001

= Nine patients (64%) had a score below 3, and five scored 4
LT IN NEUROLOGICAL WD PATIENTS: RESULTS

COPRIMARY OUTCOMES: (2) DISABILITY AT THE LAST FOLLOW-UP: UWDRS

- mean follow-up 71+/-74 months (5.8 y)
- **median UWDRS score improved**: from 96 (75-112) to 38 (18-56) (p=0.0003)
  - 60% had a major improvement
  - 30% a moderate improvement
  - 10% a mild improvement/stable status
LT IN NEUROLOGICAL WD PATIENTS: RESULTS

SECONDARY OUTCOMES AT LAST FOLLOW-UP

- ophthalmological **KFR score improved** (p=0.0007)
- **brain MRI score improved** (p=0.0007)
  - Differences depending on the location: nucleus caudate (p=0.008), pons (p=0.009), thalamus (p=0.03), mesencephalon (p=0.01)
- Serum copper and Ceruloplasmin: values normalized in all
- 24h-urinary copper excretion was slightly elevated 0.60 µmol/L (N= 0.02-0.40) in seven patients at last follow-up.

LATE COMPLICATIONS

- 1 patient: re-transplantation 7 and 11 months after the first LT due to arterial complications.
- 1 patient: developed a Burkitt lymphoma three years after LT. Considered into complete remission seven years after LT.
- 1 patient: complex partial seizures due to the extension of a cortical lesion eight months after LT. Three years after LT, epilepsy is well controlled, the UWDRS score has improved
Currently the largest cohort with a prolonged follow-up in this specific indication of pure neurological presentation

The patient survival rate
- at 1 year (88.8%) was similar to those published for LT in WD because of liver failure
- at five years (72.2%) stays reasonable since:
  - before LT,
    - patients were all bedridden and required constant nursing care
    - patients had a constant deterioration despite chelation
  - LT was proposed as a rescue treatment.

2/3 of patients had a major improvement of their neurological disability
After almost six years of follow-up:
- 64% gain physical independence for daily living activities (mRankin ≤ 3)
- 60% had a major improvement at UWDRS
- 100% had no more jejunostomy/tracheostomy

The presence of a sepsis before LT and an ICU admission within the month prior to LT could be defined as predictive factors of bad outcome (associated with a higher risk of death)
LT IN NEUROLOGICAL WD PATIENTS: CONCLUSION

• LT = a therapeutic option in **selected neurologic** WD patients resistant to decoppering therapies and without severe liver disease

• LT may not be the solution for every patient but has a place as a **rescue therapy** while waiting for future therapies

• The management of transplanted patients with severe neurologic WD is complex, and should be handled by experienced multidisciplinary teams to improve long-term survival and neurological handicap

• **Many questions remain:**
  • When should we transplant these patients ?
  • What are the good prognosis factors ?
  • What are the mechanisms underlying the effect of LT on brain dysfunction ?
  • Should chelation treatment be resumed after LT ?
National Reference Centre for WD and other rare copper diseases

Coordinator-site
University Hospital Lariboisière, Paris
http://www.cnrwilson.com/

Neurologists
Dr F Woimant
Dr P Chaine
Dr A Poujois

Molecular Biologist
Dr C Collet

Toxicologists
Dr J Poupon
Dr N Djebrani-Oussedik

Physiotherapists
Team from Neurology Department

Psychologists
Carla Machado
Elodie Jacquelet

Speech-language pathologist
Isabelle Poisson

Caregiver
Nathalie Combet

Clinical Research associate
Nadège Girardot

Secretary
Karine Le Bihan

Social Worker
Stéphanie Morel

Nurse
Hélène Petit

Assistance Publique - Hôpitaux de Paris

Maladie de Wilson
et autres maladies rares liées au cuivre
THANK YOU FOR YOUR KIND ATTENTION

Lariboisière University Hospital, Paris